SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:55da938c-7f67-4eb7-b8ee-a6d03e20087e"
 

Search: onr:"swepub:oai:lup.lub.lu.se:55da938c-7f67-4eb7-b8ee-a6d03e20087e" > Development of ACRO...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly

van der Lely, Aart Jan (author)
Erasmus University Medical Center
Gomez, Roy (author)
Pfizer Inc. US
Pleil, Andreas (author)
Pfizer Inc. US
show more...
Badia, Xavier (author)
University of Barcelona
Brue, Thierry (author)
Aix-Marseille University
Buchfelder, Michael (author)
University Hospital Erlangen
Burman, Pia (author)
Lund University,Lunds universitet,Translationell muskelforskning,Forskargrupper vid Lunds universitet,Translational Muscle Research,Lund University Research Groups,Skåne University Hospital
Clemmons, David (author)
UNC Health Care
Ghigo, Ezio (author)
Citta' della Salute e della Scienza Hospital-University of Turin
Jørgensen, Jens Otto Lunde (author)
Aarhus University
Luger, Anton (author)
Vienna General Hospital / University Hospital Vienna
van der Lans-Bussemaker, Joli (author)
Pfizer Inc. US
Webb, Susan M. (author)
Biomedical Network on Rare Diseases (CIBERER)
Strasburger, Christian J (author)
Charité - University Medicine Berlin
show less...
Erasmus University Medical Center Pfizer Inc US (creator_code:org_t)
2017-09-08
2017
English.
In: Pituitary. - : Springer Science and Business Media LLC. - 1386-341X .- 1573-7403. ; 20:6, s. 692-701
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Purpose: Despite availability of multimodal treatment options for acromegaly, achievement of long-term disease control is suboptimal in a significant number of patients. Furthermore, disease control as defined by biochemical normalization may not always show concordance with disease-related symptoms or patient’s perceived quality of life. We developed and validated a tool to measure disease activity in acromegaly to support decision-making in clinical practice. Methods: An international expert panel (n = 10) convened to define the most critical indicators of disease activity. Patient scenarios were constructed based on these chosen parameters. Subsequently, a panel of 21 renowned endocrinologists at pituitary centers (Europe and Canada) categorized each scenario as stable, mild, or significant disease activity in an online validation study. Results: From expert opinion, five parameters emerged as the best overall indicators to evaluate disease activity: insulin-like growth factor I (IGF-I) level, tumor status, presence of comorbidities (cardiovascular disease, diabetes, sleep apnea), symptoms, and health-related quality of life. In the validation study, IGF-I and tumor status became the predominant parameters selected for classification of patients with moderate or severe disease activity. If IGF-I level was ≤1.2x upper limit of normal and tumor size not significantly increased, the remaining three parameters contributed to the decision in a compensatory manner. Conclusion: The validation study underlined IGF-I and tumor status for routine clinical decision-making, whereas patient-oriented outcome measures received less medical attention. An Acromegaly Disease Activity Tool (ACRODAT) is in development that might assist clinicians towards a more holistic approach to patient management in acromegaly.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Keyword

ACRODAT
Acromegaly
AcroQoL
Patient-reported outcomes

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

  • Pituitary (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view